Regionally specific changes in levels of cortical S100β in bipolar 1 disorder but not schizophrenia

Australian and New Zealand Journal of Psychiatry

Volumn 40, Issue 3, 2006, Pages 217-224

  Dean, Brian ^a   Gray, Laura ^a   Scarr, Elizabeth ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Bipolar disorder; Cortex; Post mortem CNS; S100 ; Schizophrenia; Serotonin

Indexed keywords

CHLORPROMAZINE; FLUPENTIXOL; FLUPHENAZINE; FLUPHENAZINE DECANOATE; GLIAL FIBRILLARY ACIDIC PROTEIN; HALOPERIDOL; LITHIUM SALT; PROTEIN ANTIBODY; PROTEIN BCL 2; PROTEIN P53; PROTEIN S 100; PROTEIN S 100 BETA; RISPERIDONE; THIORIDAZINE; TRIFLUOPERAZINE; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIPOLAR I DISORDER; BRAIN CORTEX; BRAIN LEVEL; BRAIN REGION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MALE; NERVE CELL NECROSIS; NONHUMAN; PATHOGENESIS; RAT; SCHIZOPHRENIA; WESTERN BLOTTING;

ADULT; AGED; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BIPOLAR DISORDER; BRAIN MAPPING; CEREBRAL CORTEX; FEMALE; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NERVE GROWTH FACTORS; NEUROGLIA; NEURONS; PROTO-ONCOGENE PROTEINS; RISK FACTORS; S100 PROTEINS; SCHIZOPHRENIA;

EID: 33644928075     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1111/j.1440-1614.2006.01777.x     Document Type: Article

References (38)

1. Lieberman JA, Koreen AR. Neurochemistry and neuroendocrinology of schizophrenia: A selective review. Schizophrenia Bulletin 1993; 19: 371-429.
2. Sobczak S, Honig A, van Duinen MA, Riedel WJ. Serotonergic dysregulation in bipolar disorders: A literature review of serotonergic challenge studies. Bipolar Disorders 2002; 4: 347-356.
3. Azmitia EC. Modern views on an ancient chemical: Serotonin effects on cell proliferation, maturation, and apoptosis. Brain Research Bulletin 2001; 56: 413-424.
4. Wilson CC, Faber KM, Haring JH. Serotonin regulates synaptic connections in the dentate molecular layer of adult rats via 5-HT1a receptors: evidence for a glial mechanism. Brain Research 1998; 782: 235-239.
5. Sherstnev VV, Storozheva ZI, Proshin AT, Makhmutov RY, Puzyrev AV. S100B protein in pro- and antiapoptotic doses produces different effects on defensive behavior in adult rats. Bulletin of Experimental Biology and Medicine 2003; 136: 543-547.
6. Rothermundt M, Falkai P, Ponath G et al. Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF. Molecular Psychiatry 2004; 9: 897-899.
7. Rothermundt M, Missler U, Arolt V et al. Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology. Molecular Psychiatry 2001; 6: 445-449.
8. Lara DR, Gama CS, Belmonte-de-Abreu P et al. Increased serum S100B protein in schizophrenia: A study in medication-free patients. Journal of Psychiatric Research 2001; 35: 11-14.
9. Rothermundt M, Ponath G, Glaser T, Hetzel G, Arolt V. S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia. Neuropsychopharmacology 2004; 29: 1004-1011.
10. Schroeter ML, Abdul-Khaliq H, Fruhauf S et al. Serum S100B is increased during early treatment with antipsychotics and in deficit schizophrenia. Schizophrenia Research 2003; 62: 231-236.
11. Gattaz WF, Lara DR, Elkis H et al. Decreased S100-beta protein in schizophrenia: Preliminary evidence. Schizophrenia Research 2000; 43: 91-95.
12. Liu J, Shi Y, Tang J et al. SNPs and haplotypes in the S100B gene reveal association with schizophrenia. Biochemical and Biophysical Research Communications 2005; 328: 335-341.
13. Machado-Vieira R, Lara DR, Portela LV et al. Elevated serum S100B protein in drug-free bipolar patients during first manic episode: A pilot study. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology 2002; 12: 269-272.
14. Schroeter ML, Abdul-Khaliq H, Diefenbacher A, Blasig IE. S100B is increased in mood disorders and may be reduced by antidepressive treatment. Neuroreport 2002; 13: 1675-1678.
15. Pekny M, Pekna M. Astrocyte intermediate filaments in CNS pathologies and regeneration. The Journal of Pathology 2004; 204: 428-437.
16. Martin LJ. p53 is abnormally elevated and active in the CNS of patients with amyotrophic lateral sclerosis. Neurobiology of Disease 2000; 7: 613-622.
17. O'Barr S, Schultz J, Rogers J. Expression of the protooncogene bcl-2 in Alzheimer's disease brain. Neurobiology of Aging 1996; 17: 131-136.
18. Quintana J, Wong T, Ortiz-Portillo E et al. Prefrontal-posterior parietal networks in schizophrenia: Primary dysfunctions and secondary compensations. Biological Psychiatry 2003; 53: 12-24.
19. Strakowski SM, Adler CM, Holland SK, Mills N, DelBello MP. A preliminary FMRI study of sustained attention in euthymic, unmedicated bipolar disorder. Neuropsychopharmacology 2004; 29: 1734-1740.
20. Hill C, Keks N, Roberts S et al. Problem of diagnosis in postmortem brain studies of schizophrenia. American Journal of Psychiatry 1996; 153: 533-537.
21. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Washington, DC: American Psychiatric Press, 1994.
22. Dean B, Pavey G, McLeod M, Opeskin K, Keks N, Copolov D. A change in the density of [(3)H]flumazenil, but not [(3)H]muscimol binding, in Brodmann's Area 9 from subjects with bipolar disorder. Journal of Affective Disorders 2001; 66: 147-158.
23. Kingsbury AE, Foster OJ, Nisbet AP et al. Tissue pH as an indicator of mRNA preservation in human post-mortem brain. Brain Research. Molecular Brain Research 1995; 28: 311-318.
24. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proceedings of the National Academy of Sciences of the United States of America 1979; 76: 4350-4354.
25. Jarskog LF, Gilmore JH, Selinger ES, Lieberman JA. Cortical bcl-2 protein expression and apoptotic regulation in schizophrenia. Biological Psychiatry 2000; 48: 641-650.
26. Jarskog LF, Selinger ES, Lieberman JA, Gilmore JH. Apoptotic proteins in the temporal cortex in schizophrenia: High Bax/Bcl-2 ratio without caspase-3 activation. American Journal of Psychiatry 2004; 161: 109-115.
27. Catts VS, Catts SV. Apoptosis and schizophrenia: Is the tumour suppressor gene, p53, a candidate susceptibility gene? Schizophrenia Research 2000; 41: 405-415.
28. Fatemi SH, Laurence JA, Raghi-Niknam M et al. Glial fibrillary acidic protein is reduced in cerebellum of subjects with major depression, but not schizophrenia. Schizophrenia Research 2004; 69: 317-323.
29. Johnston-Wilson NL, Sims CD, Hofmann JP et al. Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium.. Molecular Psychiatry 2000; 5: 142-149.
30. Perrone-Bizzozero NI, Sower AC, Bird ED, Benowitz LI, Ivins KJ, Neve RL. Levels of the growth-associated protein GAP-43 are selectively increased in association cortices in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America 1996; 93: 14182-14187.
31. Karson CN, Casanova MF, Kleinman JE, Griffin WS. Choline acetyltransferase in schizophrenia. American Journal of Psychiatry 1993; 150: 454-459.
32. Roberts GW, Colter N, Lofthouse R, Johnstone EC, Crow TJ. Is there gliosis in schizophrenia? Investigation of the temporal lobe. Biological Psychiatry 1987; 22: 1459-1468.
33. Kleindienst A, McGinn MJ, Harvey HB, Colello RJ, Hamm RJ, Bullock MR. Enhanced hippocampal neurogenesis by intraventricular S100B infusion is associated with improved cognitive recovery after traumatic brain injury. Journal of Neurotrauma 2005; 22: 645-655.
34. Machado-Vieira R, Schmidt AP, Avila TT et al. Increased cerebrospinal fluid levels of S100B protein in rat model of mania induced by ouabain. Life Sciences 2004; 76: 805-811.
35. Margis R, Zanatto VC, Tramontina F et al. Changes in S100β cerebrospinal fluid levels of rats subjected to predator stress. Brain Research 2004; 1028: 213-218.
36. Ziegler DR, Oliveira DL, Pires C et al. Ketogenic diet fed rats have low levels of S100B in cerebrospinal fluid. Neuroscience Research 2004; 50: 375-379.
37. Unden J, Bellner J, Eneroth M, Alling C, Ingebrigtsen T, Romner B. Raised serum S100B levels after acute bone fractures without cerebral injury. Journal of Trauma 2005; 58: 59-61.
38. Wong CH, Rooney SJ, Bonser RS. S-100β release in hypothermic circulatory arrest and coronary artery surgery. The Annals Thoracic Surgery 1999; 67: 1911-1914.